Clinical Trials Browser

Bile Duct Neoplasms × Gemcitabine × 90 days × Clear all

NCT05712356 2026-05-26

BOLSTER

Phase 2 Terminated

66 enrolled 12 charts

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Disease Progression

NCT06274879 2026-05-26

Ablatio

Phase 2 Recruiting

Gastrointestinal

Bile Duct Neoplasms

NCT07030140 2026-05-01

Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma

Phase 2 Recruiting

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT05655949 2026-04-22

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Phase 2 Recruiting

Gastrointestinal

Bile Duct Neoplasms, Cholangiocarcinoma

NCT04924062 2026-04-15

KEYNOTE-966

Phase 3 Completed

158 enrolled 19 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04003636 2026-03-24

KEYNOTE-966

Phase 3 Completed

1,069 enrolled 19 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

Phase 3 Active not recruiting

Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor